Pharmaceutical Company Outlook To 2015

Pharmaceutical Company Outlook to 2015
Analysis of the top pharma and biotech companies

Use this report to assess the outlook for the
PharmaVitae Universe through to 2015
Report summary
This report provides a macro
view of the PharmaVitae Universe
over the period 2009-15
Provides company-level, life-
cycle, therapy area, and molecule
type analysis over 2009-15
Allows comparison of historical
and forecast performances by
various peer sets with
PharmaVitae Universe
Buy this report online now at
www.datamonitor.com/store
RESEARCHSTORE
Datamonitor Report
Published: Dec 10 | Code: HC00035-001
About this report
RESEARCHSTORE
Introduction
Over 200309, the PharmaVitae Universecomprised of the branded prescription pharmaceutical industrys leading companiesenjoyed robust sales
growth at a CAGR of 7.1%. The forecast period is, however, expected to be significantly more challenging with the Universe forecast a sales CAGR of
just 1.3% over 200915.
Compounding this trend has been a difficulty in developing new products, particularly those that can compensate for blockbuster expiries. Those
companies insulted from generic competitionor able to gain revenue growth sourced from biologics or the targeting of niche indications and areas of
high unmet need will emerge as key growth players.
Key findings and highlights
The PharmaVitae Universe is dominated by a number of large players: seven companiesPfizer, Merck & Co., Sanofi-Aventis, Novartis,
GlaxoSmithKline, Roche and AstraZenecagenerate annual sales in excess of $30 billion, accounting for 51.9% of total PharmaVitae Universe
sales in 2009.
Over 200915, 11 of the 43 branded pharma companies in the PharmaVitae Universe will exhibit a negative sales CAGR, with exposure to generic
competition acting as the primary barrier to revenue expansion.
Of those companies forecast to record positive growth, only six are forecast to deliver a higher sales CAGR than the historical PharmaVitae
Universe average of 7.1%, demonstrating the continued challenges faced by the industry over the next few years.
Reasons to buy
Assess the outlook for the PharmaVitae Universe through to 2015
Evaluate the factors that will drive a PharmaVitae Universe sales CAGR of 1.3% over 2009-15, versus a CAGR of 7.1% over 2003-09
Assess the differing forecast growth outlooks of each PharmaVitae peer set (Big Pharma, Mid-Pharma, Biologics and Japan Pharma)
With around 68% of 2009 PharmaVitae Universe sales derived from products
which either no longer benefit from patent protection or are exposed to the risk
of expiry by 2015, competition posed by the generics industry is a deep rooted
challenge.
Simon King, Principal Analyst - PharmaVitae
Datamonitor Report
Sample pages
RESEARCHSTORE
With the patent cliff acting as an unprecedented barrier to sales growth for
many companies, the industry has aligned itself to a number of strategies.
Supporting the fundamental drive for innovation, business diversification and
cost containment have emerged as integral policies at the corporate level.
Simon King, Principal Analyst - PharmaVitae
Datamonitor Report
Table of contents
About Datamonitor Healthcare
About the PharmaVitae team
CHAPTER 1 INTRODUCTION
Data sourcing
Further reading
CHAPTER 2 EXECUTIVE SUMMARY
Key findings
Overview of the PharmaVitae Universe outlook to 2015
Introduction to the PharmaVitae Universe
The company outlook to 2015
PharmaVitae Universe launch/core/expiry analysis
PharmaVitae Universe molecule type analysis
PharmaVitae Universe M&A analysis
CHAPTER 3 THE BIG PHARMA OUTLOOK TO 2015
Key findings
Overview of Big Pharma to 2015
Big Pharma company analysis
Big Pharma launch/core/expiry analysis
Big Pharma therapy area analysis
Big Pharma molecule type analysis
CHAPTER 4 THE MID PHARMA OUTLOOK TO 2015
Key findings
Overview of Mid Pharma to 2015
Mid Pharma company analysis
Mid Pharma launch/core/expiry analysis
Mid Pharma therapy area analysis
Mid Pharma molecule type analysis
CHAPTER 5 THE BIOTECH OUTLOOK TO 2015
Key findings
Overview of Biotech to 2015
Biotech company analysis
Biotech launch/core/expiry analysis
Biotech therapy area analysis
Biotech molecule type analysis
CHAPTER 6 THE JAPAN PHARMA OUTLOOK TO 2015
Key findings
Overview of Japan Pharma to 2015
Japan Pharma company analysis
Japan Pharma launch/core/expiry analysis
Japan Pharma therapy area analysis
Japan Pharma molecule type analysis
CHAPTER 7 APPENDIX
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer
LIST OF TABLES
Table 1: Strategic overview of the PharmaVitae Universe, 200915
Table 2: PharmaVitae Universe overview by peer set, 200915
Table 3: Launch/core/expiry analysis (percentage of 2003 sales),
200309
Table 4: Launch/core/expiry analysis (percentage of 2009 sales),
200915
Table 5: Big Pharma peer set overview, 200915
Table 6: Big Pharma launch/core/expiry portfolios, 200915
Table 7: Mid Pharma peer set overview, 200915
Table 8: Mid Pharma launch/core/expiry portfolios, 200915
Table 9: Biotech peer set overview, 200915
Table 10: Biotech launch/core/expiry portfolios, 200915
Table 11: Japan Pharma peer set overview, 200915
Table 12: Japan Pharma launch/core/expiry portfolios, 200915
Table 13: Exchange rates, 2010
LIST OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: PharmaVitae Universe prescription pharma sales ($bn) and
year-on-year growth rate (%), 2003-15
Figure 3: PharmaVitae Universe prescription pharma sales ($bn) and
year-on-year growth rate (%), 2003-15 (Big Pharma
unadjusted for M&A activity)
RESEARCHSTORE
Datamonitor Report
Table of contents (continued)
Figure 4: PharmaVitae Universe prescription pharmaceutical sales
($bn) by company, 2009
Figure 5: PharmaVitae Universe prescription pharma sales CAGR (%)
by company, 200915
Figure 6: PharmaVitae Universe prescription pharma sales ($bn) by
company, 2015
Figure 7: PharmaVitae Universe launch/core/expiry analysis, change
in sales ($bn), 200309 and 200915
in sales (% 2009) by peer set, 200915
in sales (% 2009) by company, 200915
Figure 10: PharmaVitae Universe prescription pharma sales ($bn) by
molecule type, 200315
Figure 11: PharmaVitae Universe prescription pharma sales growth
($bn) by molecule type, 200915
Figure 12: PharmaVitae Universe company-by-company prescription
pharma sales growth ($m) by molecule type, 200915
Figure 13: PharmaVitae Universe prescription pharma sales growth
($bn) by source, 200208
Figure 14: Big Pharma peer set prescription pharma sales and growth
rate, 200315
Figure 15: Big Pharma peer set landscape, 200915
Figure 16: Big Pharma peer set companies, prescription pharma sales
($m), 2009
CAGR (%), 200915
($bn), 200915
($m), 2015
Figure 20: Big Pharma peer set growth by source of product ($m),
200309
Figure 21: Big Pharma peer set launch/core/expiry, 200315
Figure 22: Big Pharma companies launch/core/expiry ($bn), 200915
Figure 23: Big Pharma companies launch/core/expiry as % of 2009
prescription pharma sales, 200915
Figure 24: Big Pharma peer set, therapy area focus, 200315
Figure 25: Big Pharma company sales by therapy area ($m), 2009
Figure 26: Big Pharma company sales by therapy area ($m), 2015
Figure 27: Big Pharma peer set, molecule type focus, 200315
Figure 28: Big Pharma peer set growth by molecule type, 200915
Figure 29: Big Pharma companies molecule type focus (% prescription
pharma sales), 2009
Figure 30: Big Pharma companies, growth by molecule type, 200915
($bn)
Figure 31: Big Pharma companies molecule type focus (% prescription
pharma sales), 2015
Figure 32: Mid Pharma peer set prescription pharma sales and growth
rate, 200315
Figure 33: Mid Pharma peer set landscape, 200915
Figure 34: Mid Pharma peer set companies, prescription pharma sales
($m), 2009
CAGR (%), 200915
($bn), 200915
($m), 2015
Figure 38: Mid Pharma peer set growth by source of product ($m),
200309
Figure 39: Mid Pharma peer set launch/core/expiry, 200315
Figure 40: Mid Pharma companies launch/core/expiry ($bn), 200915
Figure 41: Mid Pharma companies launch/core/expiry (percentage of
2009 Prescription pharma sales), 200915
Figure 42: Mid Pharma peer set, therapy area focus, 200315
Figure 43: Mid Pharma company sales by therapy area ($m), 2009
Figure 44: Mid Pharma company sales by therapy area ($m), 2015
Figure 45: Mid Pharma peer set, molecule type focus, 200315
Figure 46: Mid Pharma peer set growth by molecule type, 200915
Figure 47: Mid Pharma companies molecule type focus (% prescription
pharma sales), 2009
Figure 48: Mid Pharma companies, growth by molecule type, 200915
Figure 49: Mid Pharma companies molecule type focus (% prescription
pharma sales), 2015
Figure 50: Biotech peer set Prescription pharma sales and growth rate,
200315
Figure 51: Biotech peer set landscape, 200915
Figure 52: Biotech peer set companies, prescription pharma sales
($m), 2009
CAGR (%), 200915
($bn), 200915
($m), 2015
Figure 56: Biotech peer set growth by source of product ($m), 200309
Figure 57: Biotech peer set launch/core/expiry, ($bn), 2003-15
Figure 58: Biotech companies launch/core/expiry ($bn), 200915
Figure 59: Biotech companies launch/core/expiry (percentage of 2009
prescription pharma sales), 200915
Figure 60: Biotech peer set, therapy area focus, 200315
Figure 61: Biotech company sales by therapy area ($m), 2009
Figure 62: Biotech company sales by therapy area ($m), 2015
Figure 63: Biotech peer set, molecule type focus, 200315
Figure 64: Biotech peer set growth by molecule type, ($bn), 200915
Figure 65: Biotech companies molecule type focus (% prescription
pharma sales), 2009
Figure 66: Biotech companies, growth by molecule type, ($m), 2009
15
Figure 67: Biotech companies molecule type focus (% prescription
pharma sales), 2015
Figure 68: Japan Pharma peer set prescription pharma sales and
growth rate, 200315
Figure 69: Japan Pharma peer set landscape, 200915
Figure 70: Japan Pharma peer set companies, prescription pharma
sales ($m), 2009
sales CAGR (%), 200915
sales ($bn), 200915
sales ($m), 2015
RESEARCHSTORE
Datamonitor Report
Table of contents (continued)
Figure 74: Japan Pharma peer set growth by source of product ($m),
200309
Figure 75: Japan Pharma peer set launch/core/expiry, ($bn), 200315
Figure 76: Japan Pharma companies launch/core/expiry ($bn), 2009
15
Figure 77: Japan Pharma companies launch/core/expiry (percentage of
2009 prescription pharma sales), 200915
Figure 78: Japan Pharma peer set, therapy area focus, 200315
Figure 79: Japan Pharma company sales by therapy area ($m), 2009
Figure 80: Japan Pharma company sales by therapy area ($m), 2015
Figure 81: Japan Pharma peer set, molecule type focus, 200315
Figure 82: Japan Pharma peer set growth by molecule type, ($m),
200915
Figure 83: Japan Pharma companies molecule type focus (%
Figure 84: Japan Pharma companies, growth by molecule type, ($m),
200915
Figure 85: Japan Pharma companies molecule type focus (%
RESEARCHSTORE
Datamonitor Report
Interested in this topic?
RESEARCHSTORE
Datamonitors Company Analysis service track your competitors and identify new partners.
Qualitative and quantitative company and portfolio analysis for the leading pharmaceutical and biotechnology companies in the US, Europe, and Japan
as well as detailed analysis of key market sectors with coverage of key players.
Other reports in this series
Monoclonal Antibodies: 2010
Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule
type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules,
therapeutic proteins and vaccines. As a result, there is a strong correlation between a strong MAbs portfolio and overall company.
Published: Oct-10 | Code: HC00029-002
Generics Market Outlook: 2015
Historical and forecast analysis of the entire generics industry from 2005 through to 2015. Strategic dynamics within the sector are broken down
by company, geography, therapy area and formulation. See how Big Pharma companies' strategic shift away from blockbuster small molecule
products will impact generics companies.
Published: Oct-10 | Code: HC00030-001
For more information about these products or to browse and purchase from our huge range of research, please visit www.datamonitor.com/store.
Contact our customer service team today...
Europe tel: +44 20 7675 7764 fax: +44 20 7990 9988 email: reports@datamonitor.com
Americas tel: +1 212 686 7400 fax: +1 646 365 3362 email: reports@datamonitor.com
Middle East tel: +971 4 408 2832 fax: +971 4 335 2647 email: reports@datamonitor.com
Asia Pacific tel: +61 2 8705 6900 fax: +61 2 8705 6901 email: reports@datamonitor.com
Datamonitor Report
Place your order now...
RESEARCHSTORE
4) Sign below to confirm your order
.................................................................................................................. Date............................................
2) Complete your details
Title Mr / Mrs / Ms (delete as appropriate)
Name........................................................................................................
Job Title ...................................................................................................
Department ..............................................................................................
Company .................................................................................................
Address ...................................................................................................
City ..........................................................................................................
State/Province .........................................................................................
Post Code/ZIP .........................................................................................
Country ....................................................................................................
Email ........................................................................................................
Telephone ................................................................................................
Datamonitor products and services are supplied under Datamonitors standard terms and
conditions, copies of which are available on request. Payment must be received within 28 days
of receipt of invoice.
I do not want to receive future mailings from Datamonitor and its related companies.
I do not wish to receive phone calls from Datamonitor.
Occasionally, our client list is made available to other companies for carefully selected
mailings. Please check here if you do not wish to receive such mailings.
3) Complete your payment details
What is your preferred currency option?
UK Euro US$ Yen
How would you like to pay?
I enclose a check payable to Datamonitor for ....................
Please invoice my company for ....................
Please supply purchase order number (if required)
..................................................................................................................
If you are an EU company (except UK) please supply your
VAT / BTW / MOMS / MWST / IVA / FPA number
..................................................................................................................
X
5) Fax this completed form back
+44 20 7675 7016 (Europe) +1 646 365 3362 (Americas)
+971 4 335 2647 (Middle East) +61 8705 6901 (Asia Pacific)
Alternatively you can scan and email this form to reports@datamonitor.com
1) Confirm the license type you require
Single-user license Multi-user license (Please refer to www.datamonitor.com/store for up-to-date prices)

Pharmaceutical Company Outlook To 2015

Încărcat de

Informații document

Titlu original

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Pharmaceutical Company Outlook To 2015

Încărcat de

Drepturi de autor:

Formate disponibile

Pharmaceutical Company Outlook to 2015

Analysis of the top pharma and biotech companies

S-ar putea să vă placă și